Opens in a new tab

EOFLOW v INSULET (CFI, 24 September 2024)

Date24 September 2024
CourtCFI
DivisionMilan (IT) Central Division- Section
Type of actionApplication Rop 333
Registry referenceApp_50666/2024 · ORD_51234/2024
PartiesEOFLOW Co., Ltd.

Official decision (PDF) · UPC registry entry

Dhenne Avocats represents claimants and defendants in European patent disputes before the Unified Patent Court, including the Paris divisions.

Contact the firm

Dhenne Avocats · 10 October 2026

Our analysis

Summary

By an order of 24 September 2024 (UPC_CFI_380/2024), the panel of the Milan Central Division (A. Postiglione, presiding judge and judge-rapporteur, A.-L. Klein, U. Schwengelbeck), seised by EOFLOW Co., Ltd. under Rule 333, approved the judge-rapporteur’s order of 4 September 2024 (App_48857/2024) refusing to join INSULET Corporation’s application for provisional measures based on EP 4 201 327 with the parallel case brought before the Milan Local Division against the Italian distributor MENARINI. Leave to appeal was granted. The order sets the framework for joinder under Article 33 UPCA and Rule 340.

Question

Outside the cases of mandatory consolidation under Article 33 UPCA, is a party entitled to have provisional measures proceedings joined with a parallel case, and may the judge-rapporteur decide alone?

Decision

Outside Article 33(2) and (4), joinder is a discretionary case management measure, to be exercised proportionately. No party has a right to it (paragraphs 14 to 16 and 23). The risk of divergent decisions is minimal, since the same two judges sit on both panels, and provisional measures orders have no res judicata effect and may be revoked (paragraphs 17 to 22). Findings on validity remain provisional (paragraphs 24 to 27). Holding the hearings in parallel met EOFLOW’s concerns (paragraph 28). As to Rule 340, an order granting joinder is for the panel, as it affects the other proceedings. A refusal, which requires only consultation, may be made by the judge-rapporteur (Rule 1.2) (paragraphs 29 to 42).

Key points for practice

Provisions applied

Agreement on a Unified Patent Court
Art. 33(1)(b), (2) and (4) and Art. 73(2)(b)
Rules of Procedure
Rules 1.2, 198.1, 211.2, 211.3, 213, 220.2, 224.1, 302, 333, 340, 361 and 362
Case law cited
Court of Appeal, 5 September 2024, UPC_CoA_106/2024

Prepared by Dhenne Avocats from the official decision, consulted on 10 October 2026. The database is updated every week, on Friday. Only the official text is authoritative.


Going further

Lexicon: Supplementary protection certificate (SPC), Biosimilar medicinal product, Launch at risk.

Dhenne Avocats blog: Pharmaceutical patents and the UPC: is the Court hostile to them?.

Publications by Matthieu Dhenne: The Launch Letter: How Generics and Biosimilars Should Write to Avoid UPC Urgency (Kluwer Patent Blog).

Source and translations

Official source
Unified Patent Court registry link recorded in the record
Original language
not recorded
Translation available
no translation recorded the firm’s French record is a summary, not a translation
Date checked
not recorded
Only the official text is authoritative. A machine translation is never presented as official, republishing a third-party document requires a verified basis in rights, and a link to the source is preferred.

Follow this case

Proceedings, related decisions, appeals, parties and patents as recorded in the registry and in the Dhenne Avocats corpus. Each link states its source.

Proceedings

No case number recorded in this record.

Parties

Exact name as it appears in the record, group affiliation only where sourced and dated.

Decisions in the same proceedings and documented appeals

No other decision in the corpus bears the same case number, and no appeal is documented in the corpus to date.

What the record states

Nature of the act
Application Rop 333
Outcome (Dhenne Avocats summary)
Hors des cas de l'article 33 de l'Accord, la jonction est discrétionnaire et aucune partie n'y a droit. Le refus de jonction du juge rapporteur est approuvé, et l'appel est autorisé.
Appeal
No appeal documented in the corpus, this does not mean that no appeal was lodged.
Instance
First-instance decision, whether it has become final is not recorded.

Patents mentioned

Scope: Dhenne Avocats corpus. Registry-based links are marked “official number”; links derived from the analyses are marked as such. An erroneous link can be withdrawn without deleting any record.

Patents and standards

PublicationRole in the disputeFamilyStandard and declarationPoolSources
EP 4 201 327
Fluid delivery device with transcutaneous access tool, insertion mechanism and blood glucose monitoring for use therewith
recorded proprietor: Insulet Corp
Mentioned in the analysis (role not qualified)
Also mentioned in 25 other decision(s): EOFLOW v Insulet (CFI, 22 July 2025) · EOFLOW v Insulet (CoA, 18 March 2026) · EOFlow v Insulet (CoA, 26 February 2026) · EOFlow v Insulet (CoA, 4 February 2026) · EOFlow v Insulet (CoA, 29 January 2026) · Herbert Smith Freehills Kramer (applicant) in Insulet v EOFLow (CoA, 2 · Insulet v EOFLOW (CFI, 15 October 2025) · EOFLOW v Insulet (CFI, ORD_26828/2025, 5 June 2025)
not recordednot recordednot recordedEspacenet · European Patent Register
existence and title of the publication checked on 30 October 2026 (Google Patents, Espacenet and Register links are not checked automatically)
mentioned in: Dhenne Avocats analysis
The statuses “asserted in litigation”, “declared essential”, “listed by a pool” and “essentiality examined by a court” are distinct and may coexist. Validity, infringement and technical essentiality are different questions. Scope: patents cited in the decisions of the Dhenne Avocats corpus, with no essentiality score or prediction.

Receive an alert

Weekly summary of new records and substantive updates matching what you follow. Address confirmed by email, unsubscribe at any time, one email per week even where several of your follows match.

Follow

Weekly summary, on Fridays.